Title: A Phase 2 Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer1
Principal Investigator: Jochen Lorch, MD, Dana-Farber Cancer Institute
Description: For this open label phase 2 study (ClinicalTrials.gov Identifier: NCT02657551), researchers are investigating the efficacy and safety of regorafenib, an orally-administered multi-kinase inhibitor, among patients with metastatic medullary thyroid cancer who received at least 1 prior therapy.
Continue Reading
There is 1 trial arm: oral, daily predetermined regorafenib dosage for 3 weeks per cycle.
Primary outcomes are response and progression-free survival. Secondary outcomes are safety, radiographic response, and response-associated biomarkers.
For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02657551.
Status: This study is open and recruiting patients as of February 2, 2017.
Regorafenib is approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal cancer and advanced or unresectable gastrointestinal stromal tumors.
Reference
- Clinicaltrials.gov. A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer. NCT02657551. https://clinicaltrials.gov/ct2/show/NCT02657551 Accessed February 2, 2016.
